Published in Ther Clin Risk Manag on February 01, 2008
Vitamin D3-driven signals for myeloid cell differentiation--implications for differentiation therapy. Leuk Res (2009) 1.00
Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery. Int J Nanomedicine (2010) 0.86
Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol (2012) 0.84
Topical medication utilization and health resources consumption in adult patients affected by psoriasis: findings from the analysis of administrative databases of local health units. Clinicoecon Outcomes Res (2017) 0.75
[Not Available]. Ther Clin Risk Manag (2008) 0.75
Successful treatment of refractory chronic hand eczema with calcipotriol/betamethasone ointment: A report of three cases. Exp Ther Med (2015) 0.75
Treatment of mites folliculitis with an ornidazole-based sequential therapy: A randomized trial. Medicine (Baltimore) (2016) 0.75
Topical Therapies in Psoriasis. Indian Dermatol Online J (2017) 0.75
Calcipotriene/betamethasone dipropionate for the treatment of psoriasis vulgaris: an evidence-based review. Clin Cosmet Investig Dermatol (2017) 0.75
Gene regulation by steroid hormones. Cell (1989) 12.96
Psoriasis. N Engl J Med (2005) 8.56
Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol (2005) 3.11
Psoriasis. Lancet (2003) 3.05
Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet (1991) 2.72
Psoriasis--epidemiology and clinical spectrum. Clin Exp Dermatol (2001) 2.56
The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/ Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial. Br J Dermatol (2004) 1.53
Age at onset and different types of psoriasis. Br J Dermatol (1995) 1.52
The pathomechanisms of psoriasis; the skin immune system and cyclosporin. Br J Dermatol (1988) 1.32
A dual mechanism mediates repression of NF-kappaB activity by glucocorticoids. Mol Endocrinol (1998) 1.20
Inhibition of production and function of interleukin-6 by 1,25-dihydroxyvitamin D3. Immunol Lett (1991) 1.19
Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol (2004) 1.17
Current consensus and update on psoriasis therapy: a perspective from the U.S. J Dermatol (1999) 1.05
A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol (2006) 1.01
A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol (1992) 1.01
A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol (2002) 1.01
Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol (2003) 0.98
A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis. Br J Dermatol (1994) 0.98
Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol (1992) 0.96
Development of a new formulation combining calcipotriol and betamethasone dipropionate in an ointment vehicle. Drug Dev Ind Pharm (2004) 0.95
Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol (2004) 0.95
Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. Dermatology (2006) 0.91
Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial. Am J Clin Dermatol (2006) 0.89
A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology (2002) 0.88
A review of the epidemiology of psoriasis vulgaris in the community. Australas J Dermatol (1998) 0.88
1 alpha,25-Dihydroxyvitamin D3 and a novel vitamin D analogue MC 903 are potent inhibitors of human interleukin 1 in vitro. Immunol Lett (1988) 0.88
Consistency of data in six phase III clinical studies of a two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis. J Eur Acad Dermatol Venereol (2006) 0.87
Biological activity of vitamin D analogues in the skin, with special reference to antipsoriatic mechanisms. Br J Dermatol (1995) 0.86
The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis. Exp Dermatol (2004) 0.86
Psoriasis: severity assessment in clinical practice. Conclusions from workshop discussions and a prospective multicentre survey of psoriasis severity. Eur J Dermatol (2006) 0.83
The atrophogenic potential and dermal tolerance of calcipotriol/betamethasone dipropionate ointment compared with betamethasone dipropionate ointment. Dermatology (2003) 0.83
Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol (2004) 0.83
Calcipotriol/betamethasone dipropionate for the treatment of psoriasis. Expert Opin Pharmacother (2006) 0.83
Effect of calcitriol on the production of T-cell-derived cytokines in psoriasis. Br J Dermatol (1997) 0.82
A two-compound product containing calcipotriol and betamethasone dipropionate provides rapid, effective treatment of psoriasis vulgaris regardless of baseline disease severity. Dermatology (2005) 0.82
Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol (1994) 0.81
Cost-effectiveness of once-daily treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol in the treatment of Psoriasis vulgaris. Dermatology (2005) 0.79
Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris. Am J Clin Dermatol (2004) 0.79
Efficacy and local safety of a calcipotriol/ betamethasone dipropionate ointment in elderly patients with psoriasis vulgaris. Eur J Dermatol (2005) 0.79
Vitamin D3 and calcipotriol enhance the secretion of transforming growth factor-beta 1 and -beta 2 in cultured murine keratinocytes. Growth Factors (1993) 0.78
Molecular evaluation of vitamin D3 receptor agonists designed for topical treatment of skin diseases. J Invest Dermatol (2001) 0.78
Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology (2004) 0.78
Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004. J Cutan Med Surg (2005) 0.78
Bioavailability of betamethasone dipropionate when combined with calcipotriol. Int J Dermatol (2004) 0.77
Topical therapy for psoriasis with the use of augmented betamethasone and calcipotriene on alternate weeks. J Am Acad Dermatol (2000) 0.77
Calcipotriol (Dovobet) ointment in combination with UVB therapy for psoriasis treatment. Dermatol Nurs (2006) 0.77
Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment. Int J Dermatol (2006) 0.77
The topical treatment of psoriasis. Skin Pharmacol Appl Skin Physiol (2003) 0.77
Effects of topical treatment with budesonide on parameters for epidermal proliferation, keratinization and inflammation in psoriasis. J Dermatol Sci (1995) 0.76
Long-term effectiveness and safety of topical calcipotriene for psoriasis. Calcipotriene Study Group. South Med J (1996) 0.76
Treatment of psoriasis with a new combination of calcipotriol and betamethasone dipropionate: a flow cytometric study. Dermatology (2001) 0.76
Effect of pigmentation on photodynamic therapy. Lancet Oncol (2013) 1.08
Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clin J Pain (2013) 0.83
Spontaneous abortion during ustekinumab therapy. J Dermatol Case Rep (2012) 0.82
Persistent erythematous lesion of the vulva: a diagnostic and treatment challenge. J Drugs Dermatol (2012) 0.82
Efficacy of adalimumab in recalcitrant hidradenitis suppurativa. Eur J Dermatol (2009) 0.80
Pemphigus vegetans of the tongue: a diagnostic and therapeutic challenge. Int J Dermatol (2013) 0.79
Ustekinumab for the treatment of an adolescent patient with recalcitrant plaque psoriasis. Eur J Dermatol (2011) 0.77
Congenital nevus of the nail apparatus--diagnostic approach of a case through dermoscopy. Pediatr Dermatol (2012) 0.75
Zosteriform cutaneous metastasis of breast carcinoma in a male patient. Int J Dermatol (2014) 0.75